Related Experiment Video

Updated: Oct 8, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Novel approaches in the treatment of non-small-cell lung cancer

R Rosell1, J M Sánchez, M Tarón

  • 1Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

Oncology (Williston Park, N.Y.)
|April 17, 2001
PubMed

Insights

Genetic abnormalities in non-small cell lung cancer can cause resistance to cytotoxic drugs, making standard treatments ineffective. Identifying these genetic markers can personalize chemotherapy for better patient outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Genetic abnormalities are increasingly recognized as key mechanisms of drug resistance in cancer treatment.
  • Non-small cell lung cancer (NSCLC) treatment efficacy can be limited by inherent or acquired resistance to cytotoxic agents.
  • Specific genetic markers have shown utility in predicting treatment response in other cancers, such as colorectal cancer.

Purpose of the Study:

  • To explore the role of genetic abnormalities in predicting and overcoming drug resistance in non-small cell lung cancer.
  • To identify specific genetic markers that can serve as surrogates for treatment response to cytotoxic chemotherapy.
  • To propose further studies for validating these genetic markers in customized chemotherapy regimens.

Main Methods:

  • Review of existing data on genetic abnormalities and drug resistance in non-small cell lung cancer.
  • Identification of specific genetic markers associated with resistance to common chemotherapeutic agents (e.g., thymidylate synthase mRNA, ERCC1 mRNA, beta-tubulin mutations).
  • Exploration of genetic targets for gemcitabine resistance, focusing on the ribonucleotide reductase gene in chromosome 11p15.5.

Main Results:

  • Certain genetic abnormalities can confer early-stage resistance to specific cytotoxic drugs in non-small cell lung cancer.
  • Thymidylate synthase mRNA and ERCC1 mRNA levels are potential surrogate markers for treatment response, particularly noted in colorectal cancer.
  • Beta-tubulin mutations may predict paclitaxel resistance, and the ribonucleotide reductase gene region on chromosome 11p15.5 is a potential target for gemcitabine resistance.

Conclusions:

  • Prescribing certain cytotoxic chemotherapy combinations to a majority of non-small cell lung cancer patients may be futile due to genetic resistance mechanisms.
  • Validation of identified genetic markers through customized chemotherapy studies is crucial for improving treatment strategies.
  • Personalized medicine approaches, guided by genetic profiling, hold promise for enhancing the efficacy of lung cancer treatment.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...